Cargando…
Efficacy and safety in mice of repeated, lifelong administration of an ANGPTL3 vaccine
Previously, we reported that an ANGPTL3 vaccine is a hopeful therapeutic option against dyslipidemia. In our current study, we assess durability and booster effects of that vaccine over a period representing a mouse’s lifespan. The vaccine remained effective for over one year, and booster vaccinatio...
Autores principales: | Fukami, Hirotaka, Morinaga, Jun, Nakagami, Hironori, Hayashi, Hiroki, Okadome, Yusuke, Matsunaga, Eiji, Kadomatsu, Tsuyoshi, Horiguchi, Haruki, Sato, Michio, Sugizaki, Taichi, Miyata, Keishi, Torigoe, Daisuke, Mukoyama, Masashi, Morishita, Ryuichi, Oike, Yuichi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10620388/ https://www.ncbi.nlm.nih.gov/pubmed/37914738 http://dx.doi.org/10.1038/s41541-023-00770-3 |
Ejemplares similares
-
Vaccine targeting ANGPTL3 ameliorates dyslipidemia and associated diseases in mouse models of obese dyslipidemia and familial hypercholesterolemia
por: Fukami, Hirotaka, et al.
Publicado: (2021) -
Association of circulating ANGPTL 3, 4, and 8 levels with medical status in a population undergoing routine medical checkups: A cross-sectional study
por: Morinaga, Jun, et al.
Publicado: (2018) -
ANGPTL2 promotes immune checkpoint inhibitor-related murine autoimmune myocarditis
por: Horiguchi, Haruki, et al.
Publicado: (2023) -
ANGPTL2 expression in the intestinal stem cell niche controls epithelial regeneration and homeostasis
por: Horiguchi, Haruki, et al.
Publicado: (2017) -
Aging- and obesity-related peri-muscular adipose tissue accelerates muscle atrophy
por: Zhu, Shunshun, et al.
Publicado: (2019)